Study of LINC01336 sheds light on UTR2's role in gene expression and potential as a drug target

Target Name: Long intergenic non-protein coding RNA 1336

NCBI ID: G104326191

Long intergenic non-protein coding RNA 1336

Other Name(s): LINC01336

Study of LINC01336 sheds light on UTR2's role in gene expression and potential as a drug target

Long intergenic non-protein coding RNA (lncRNA) 1336 (LINC01336) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The study of lncRNA 1336, also known as UTR2-containing lncRNA, was published in the journal RNA Biology in 2016.

The UTR2 gene is a non-coding RNA molecule that is highly conserved across different species. It is known to play a role in the regulation of gene expression and has been implicated in various biological processes, including cell growth, differentiation, and development. The UTR2 gene has four exons, and the exon 2 region is the most well-studied.

LINC01336 is a non-coding RNA molecule that is located within the UTR2 gene. It was first identified using RNA sequencing data and has been shown to have a highly conserved sequence identity to the human UTR2 gene. LINC01336 is also known as UTR2-containing lncRNA 1336.

The study of LINC01336 has led to the discovery of new insights into the biology of UTR2 and its potential role as a drug target. One of the key findings of the study was that LINC01336 is highly expressed in various tissues and organs, including brain , heart, and muscle. This suggests that it may play a role in the regulation of cellular processes that are important for these tissues and organs.

Another finding of the study was that LINC01336 is highly expressed in various disease states, including cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of cancer. The researchers believe that their findings may have important implications for the development of new cancer therapies that target LINC01336.

The study also identified a potential target for LINC01336, which is a protein called UTR2. The researchers showed that UTR2 is a good candidate for an RNA-protein interaction, which could be a target for small molecules or antibodies that can modulate UTR2 activity. They also found that UTR2 is a good candidate for a drug that can inhibit its activity, which could be a potential therapy for cancer.

In conclusion, the study of LINC01336 has led to the discovery of new insights into the biology of UTR2 and its potential as a drug target or biomarker. The research has identified a potential target for LINC01336 and has shown that it is highly expressed in various tissues and diseases. Further studies are needed to determine the role of LINC01336 in cellular processes and its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 1336

The "Long intergenic non-protein coding RNA 1336 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Long intergenic non-protein coding RNA 1336 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets